I. INTRODUCTION
MicroRNAs (miRNAs) are a class of endogenous singlestranded non-coding RNA (∼22 nt) molecules. Studies have demonstrated that the miRNAs play critical roles in posttranscriptional regulations and in many pathological and biological processes [1] , [2] . The mutation and dysregulated expression of miRNAs may be associated with the human complex diseases [3] - [5] . However, experimental identification of disease-associated miRNA candidates is a timeconsuming and tremendously expensive process. Therefore, predicting the potential miRNA-disease associations by computational methods will contribute to exploring the pathogenesis of diseases and benefit disease diagnosis and treatment.
In recent years, the relationships between miRNAs and diseases have been extensively investigated. Jiang et al. [6] first presented a similarity-based model that quantifies the miRNA functional similarity based on the overlap of their associated target genes and prioritized the disease miRNA candidates by the hypergeometric distribution. Li et al. [7] obtained miRNA target genes from target prediction programs, and then identified the disease-related miRNA candidates by measuring the functional consistency scores among miRNA targets and those targets related to the diseases. Xu et al. [8] developed a computational method, that extracts different feature vectors based on topological properties, and applied support vector machine (SVM) to infer miRNA-disease associations. However, obtaining the experimentally verified negative samples is not easy or impossible. Shi et al. [9] recently presented a prediction model by exploiting the functional associations between the known disease genes and miRNA target genes in PPI network. Unfortunately, the aforementioned approaches based on the target genes experience difficulties in achieving significant performance because these target prediction programs have relatively high false-positive and false-negative rates [10] , [11] , such as TargetScan [12] and PITA [13] . The functionally similar miRNAs are normally related to similar diseases and vice versa [14] - [16] . Based on the above observation, Chen et al. [17] presented a prediction model named RWRMDA and adopted a global network information to capture the candidate disease-related miRNAs by using random walk with restart algorithm. In addition, Xuan et al. [18] proposed an effective prediction algorithm called HDMP, which utilizes the miRNA family or cluster information and considers the weighted k most similar neighbor nodes in identifying the potential disease-related miRNAs. Luo et al. [19] presented an unbalanced bi-random walk-based algorithm on the heterogeneous network to discover the relationships between miRNAs and diseases by exploiting bipartite subgraphs. Xuan et al. [20] constructed a weighted miRNA network in which nodes are divided into two categories according to whether these nodes have known associations with given diseases, and then developed a new prediction model named MIDP. The model is based on random walk and assigns different transition weights for the two categories during the iterative process. Furthermore, the authors proposed another prediction method named MIDPE that could effectively predict miRNA candidates for diseases without any known association [20] . Luo et al. [21] developed a collection prediction method based on transduction learning to predict potential associations for diseases with sparsely known miRNAs. In addition, Chen et al. [22] proposed another computational model called WBSMDA and utilized Within-scores and Between-scores of each miRNAdisease pair for prioritization of disease-associated miRNAs. However, the performance of the above models needs improvement and most of them strongly rely on known miRNA-disease associations. The advanced approaches could not generate predictions because the experimentally verified associations are not always available.
In this work, we developed a novel prediction model called KRLSM, which adopts the comprehensive similarity measures to estimate the similarity for diseases and miRNAs by fully utilizing the multiple omics data, and employs the Kronecker regularized least squares to prioritize the disease miRNA candidates. In contrast to earlier methods, our similarity measures are not only completely dependent on known association information, thus effectively reducing the reliance on validated associations. The hierarchical directed acyclic graphs (DAGs) about diseases, the known miRNA-disease associations, the experimentally determined miRNA-gene interactions, and the weighted gene-gene network are incorporated to quantify the similarities for diseases and miRNAs. Then, we combine the miRNA similarity matrix and disease similarity matrix into a whole Kronecker product similarity matrix, and an effective machine learning method, i.e., the regularized least squares, is used to train the prediction model. The experimental results of the cross validations, simultaneous global prediction for all diseases, de novo miRNA-disease prediction, and case studies indicate the capability of KRLSM for inferring the missing miRNAdisease associations. 
II. MATERIALS AND METHODS

A. METHODS OVERVIEW
First, the disease similarity is calculated by integrating the MeSH's hierarchical structure information [15] and the known miRNA-disease associations, whereas the miRNA similarity is calculated by using the known miRNA-disease associations, the experimentally determined miRNA-gene interactions and the weighted gene-gene network. Second, the semi-supervised framework of KRLSM is applied to obtain the relevance scores between diseases and miRNAs. Finally, we rank the miRNAs for a given disease and analyze whether they are associated with the disease. Figure 1 describes the overall workflow of our method.
B. DATA COLLECTION AND PREPROCESSING
The relationships among diseases are obtained from MeSH database (https://www.nlm.nih.gov/mesh/), which is used to calculate the disease semantic similarity according to the hierarchical structure about diseases. The gold standard dataset is downloaded from HMDD v2.0 [23] , by combining the multiple miRNA transcripts to the same mature miRNA as done in previous studies [20] , [22] , which includes 5424 associations between 495 miRNAs and 378 diseases. Considering several irregularly named diseases, 330 out of 378 diseases are included in the MeSH database. As some computational prediction programs usually have high false-positive and false-negative rates, in this work, we obtain the miRNA target genes from three experimentally verified databases, including miRecords (version 4.0) [24] , miRTarBase (version 4.5) [25] and TarBase (version 6.0) [26] , After inhibiting the duplicated interactions, 38089 miRNAgene interactions involving 477 miRNAs and 12422 genes are obtained, note that those miRNAs are not considered if they are not involved in HMDD. The weighted gene-gene network is derived from HumanNet (http://www. functionalnet.org/humannet/) [27] , which is a probabilistic functional gene network and contains 476399 interactions among 16243 genes. In addition, the source code of KRLSM is freely available at https://github.com/XIAO-HN/KRLSM.
C. DISEASE SIMILARITY MEASUREMENT
Disease similarity has been widely applied for numerous biological studies, such as in measuring similarity for miRNAs [15] , predicting potential associations between miRNAs and diseases [20] , identifying cancer-related genes [28] , and discovering new drug indications [29] . Most of the existing methods only consider the disease semantic similarity and many elements in the semantic similarity matrix are zero. In this section, we optimize the similarity measurement by incorporating heterogeneous omics data and the procedure of disease similarity calculation is mainly composed of three steps:
Step 1 (Calculating Disease Semantic Similarity): The semantic similarity of each disease pair is estimated according to the similarity strategy in Wang et al. [15] , which is based on the hierarchical directed acyclic graphs obtained from MeSH. Formally, a given disease d can be denoted as
, in which the diseases are linked from a general one to a more specific one. T(d) denotes the disease set including disease d itself and its ancestors, and E(d) stands for the set of the links between disease d with others in DAG d .
The semantic contribution of disease t to disease d is calculated as follows:
where is the semantic contribution factor ( = 0.5) [15] .
As shown in Eq. (1), the farther the ancestor node distance from disease d, the smaller the contribution to the semantic value of disease d. Based on the assumption that the two diseases sharing a large part of their hierarchical structures could probably gain a higher similarity, the semantic similarity between diseases d i and d j is defined as follows:
Step 2 (Gaussian Interaction Profile Kernel Similarity for Diseases): Existing studies have demonstrated that similar diseases often exhibit a similar correlation pattern with miRNAs, thus we consider the network topological similarity and calculate Gaussian interaction profile (GIP) kernel similarity for diseases based on the known miRNA-disease 
where parameter γ d is the kernel bandwidth. It is obtained by normalizing a new bandwidth parameter γ d by the average number of associations with miRNA per disease. n d is the number of diseases. The parameter γ d is calculated as follows:
Finally, the matrix GS D is the GIP similarity matrix for all diseases. GS D (d i , d j ) stands for the kernel similarity between diseases d i and d j .
Step
(Integrating Disease Semantic Similarity and Gaussian Interaction Profile Kernel Similarity for Diseases):
As aforementioned, a number of similarity scores in the disease semantic similarity matrix are zero. To illustrate this problem, 10 diseases are randomly selected from among 330 different diseases and the number of semantic similarity scores above zero with the other 329 diseases is counted, as shown in Table 1 . The result indicates that only a part of diseases is related to other diseases by the semantic similarity measurement, despite many of them are actually closely related. Under the circumstance, we adopt the integrated similarity measures to estimate the similarity between any two diseases. We calculate the similarity between diseases d i and d j as follows:
where υ ∈ [0, 1] is the weight coefficient. DT represents the common disease set obtained from MeSH and HMDD, and the number of diseases in DT is 330 in this study.
D. MiRNA SIMILARITY MEASUREMENT
An increasing number of studies have reported that miRNAs associated with similar diseases normally have similar functions [15] , [20] . The most common miRNA similarity measurements for miRNA-disease association prediction are based on the overlapping miRNA-associated diseases [30] , which quantify the miRNA similarity using disease semantic similarity and known miRNA-disease associations. However, these similarity metrics strongly rely on available associations. Thus, they are unable to estimate similarity for novel miRNAs without any associated diseases. Considering this circumstance, we develop a new measurement to integrate the weighted gene functional interaction network, the experimentally verified miRNA-target gene interactions and the known miRNA-disease associations to quantify the miRNA similarity.
Similarly, we measure the similarity between miRNAs m i and m j according to the following formula:
where FS M (m i , m j ) and GS M (m i , m j ) represent the functional similarity based on target genes and the GIP kernel similarity between m i and m j . MT stands for the common miRNA set acquired from three experimentally verified databases (miRecords, miRTarBase and TarBase) and HMDD. ω ∈ [0, 1] is the weight coefficient to balance the miRNA similarity based on target genes and the Gaussian kernel similarity for miRNAs. First, the miRNA functional similarity matrix FS M is obtained through the experimentally verified miRNA-target gene interactions and the weighted gene functional interaction network. The gene interaction network is obtained from HumanNet, in which the associated log-likelihood scores (LLS) of each edge are used to measure the strength of interaction between any two genes. We normalize LLS(g i , g j ) and get the normalized similarity LLS(g i , g j ) between genes g i and g j as follows:
where LLS min and LLS max denote the minimum and maximum LLS in HumanNet, respectively. The functional similarity of gene g i and gene g j is given as follows:
where e(g i , g j ) is the functional linkage between g i and g j . Based on the way in [15] for measuring the similarity between one disease and a disease group, we calculate the similarity between gene g t and gene set GT={g t1 , g t2 , . . . , g tk } as follows:
After that, the functional similarity FS M (m i , m j ) based on the common genes is defined according to the best matching average (BMA) strategy [31] - [33] , which is calculated as follows:
where GT 1 and GT 2 denote the gene set associated with m i and m j , respectively.
Finally, in the same manner, the Gaussian kernel similarity for miRNAs can be calculated as follows:
where M mi is a binary vector applied to denote whether miRNA m i is related to each disease in the known association network. The parameter γ m controls the kernel bandwidth for different miRNAs, which can be obtained by normalizing a new bandwidth parameter γ m by the average number of associations with disease per miRNA. n m stands for the number of miRNAs.
E. KRONECKER REGULARIZED LEAST SQUARES FOR miRNA-DISEASE ASSOCIATIONS
The identification of potential associations can be modeled as a link prediction problem. Here, A method called KRLSM is presented to obtain the relevance scores between miRNAs and diseases based on the Kronecker product and the regularized least squares classifier. Inspired by Pahikkala et al. [34] , we first adopt the algebraic properties of Kronecker product and combine the miRNA space and the disease space into a whole miRNA-disease space for predictions. The Kronecker product similarity matrix S = S M ⊗ S D and the elements of matrix S are calculated as follows:
Assuming that |M| and |D| stand for the number of miRNAs and diseases, respectively. Hence, the size of the Kronecker product similarity matrix S is |M||D| × |M||D|. R is the original adjacency matrix of the miRNA-disease associations. With the combination of Kronecker product and the RLS classifier, the optimization problem of KRLSM can be concluded in the miRNA-disease space as follows:
where F md = vec(R T ). ||.|| F represents the Frobenius norm, and vec(.) is a vector operation by stacking the columns of a matrix into a vector. σ stands for the regularization parameter. The solution of the above optimization problem can be obtained according to:
where I is an identity matrix with the same size of matrix S.
In this study, we set σ = 1 according to the selection in [34] . To significantly reduce the computational complexity, an acceleration technique named 'vec-trick' is used to speed up the model training as performed in [35] , which is based on the following property of the Kronecker product, vec(AXB)= (B T ⊗ A)vec(X). Therefore, we can transform Eq. (14) into:
where
Finally, we obtain the prediction for KRLSM by the following equation:
From Eq. (16), the prediction based on Kronecker regularized least squares only needs some matrix multiplications and implements two eigen decompositions. The time complexity is reduced from O((|M||D|) 3 ) to O(|M| 3 + |D| 3 ) by applying the 'vec-trick'. The value of entity ∧ * R (i, j) stands for the correlation score between miRNA i and disease j. The miRNAs with top rank of each disease are treated as the potential miRNAs for further experimental confirmation and investigation.
III. RESULTS AND DISCUSSION
A. EVALUATION METRICS
To systematically evaluate the performance of KRLSM and other compared methods, five-fold cross validation is performed on the gold standard dataset. In each repetition of the cross validation experiments, for a special disease d, the known d-related miRNAs are randomly divided into five subsets of equal size, one subset is used in turn as the test set and the remaining four subsets are the training set. For the reasons that the similarity measures for miRNAs and diseases are related to the known miRNA-disease associations, the integrated miRNA similarity matrix and the disease similarity matrix are recalculated in different experimental scenarios. The area under ROC curve (AUC) is used as the main metric for evaluating the performance.
In principle, the top-ranked prediction results are more essential than other portions, we also count up the number of known miRNA-disease associations that are correctly retrieved under various top-ranked thresholds to estimate the performance of all prediction methods. Usually, the computational method is more effective if most true associations are obtained from the top portions. Moreover, with the rapidly increasing number of new miRNAs or diseases being discovered, the known association information about these miRNAs or diseases are quite limited, or even in the absence of known related disease or miRNA for facilitating to infer potential associations. Therefore, de novo miRNA-disease predictions are implemented to further evaluate the ability of different approaches for discovering potential associations for these novel diseases. 
B. THE EFFECT OF WEIGHT COEFFICIENTS ON KRLSM PERFORMANCE
Five parameters are introduced in our method. Parameters γ d and γ m are the new kernel bandwidths, which control the calculation of GIP kernel similarity for diseases and miRNAs, respectively. Parameter σ represents the regularization parameter for RLS. In this article, we set γ d = γ m = 1 and σ = 1 according to the previous study [35] . Parameters υ and ω are the weight coefficients that are employed to incorporate different similarity measures. Here, to explore the impact of these two parameters on the prediction performance, we fix other parameters and vary the value of υ or ω in five-fold cross validation experiments. Figure 2 illustrates the average AUC obtained by KRLSM with respect to different values of υ and ω. As we can see that KRLSM achieves the optimal AUC values when υ = 0.7 (Figure 2(A) ) and ω = 0.8 (Figure 2(B) ), respectively. More detailed information is given in Supplementary Table S1 . When setting υ as 0 (or 1), the AUC value obtained by KRLSM is 0.841 (or 0.811). The average AUC values achieved by KRLSM are 0.521 and 0.833 by setting ω as 0 and 1, respectively. The experiment results show that the best performance is obtained when the weight coefficients of both υ and ω are not equal to 0 or 1, which demonstrates the effectiveness of fully utilizing heterogeneous omics data for disease-related miRNA identification. 
C. COMPARISON WITH OTHER METHODS
1) CROSS VALIDATION
To comprehensively evaluate the efficiency of KRLSM in discovering potential candidate miRNAs, we compare it with three state-of-art methods: RWRMDA [17] , MIDP [20] , and MIDPE [20] . The parameters of RWRMDA, MIDP, and MIDPE are chosen as used in each method (r = 0.9 for RWR-MDA, r Q = 0.4 and r U = 0.1 for MIDP, α = 0.9 and γ = 0.8 for MIDPE). As the three methods adopted the earlier version of databases, we recalculated the similarity of any two diseases or miRNAs based on the latest version databases, which are also used in our study. As aforementioned, the confirmed 5424 miRNA-disease associations cover 378 diseases. The maximum number of associations related to a disease is 214, whereas the minimum number is 1. In order to obtain fair and reasonable evaluation results, five-fold cross validations were implemented in two different experiment scenarios, first for the 22 diseases that are related to at least 60 confirmed associations, second for all the diseases consisting of at least 10 known disease-related miRNAs.
The ROC curves of the four methods in the first experiment scenario are shown in Figure 3(A) . The average AUC values of KRLSM, RWRMDA, MIDP, and MIDPE are 0.853, 0.801, 0.833, and 0.821, respectively. KRLSM achieves the best result, and its average AUC values are 5.2%, 2.0% and 3.2% higher than other three computational approaches. Meanwhile, the AUC values of the 22 diseases are also listed in Table 2 . Figure 3 (B) displays the ROC curves and average AUC values for the second experiment scenario. The performance of KRLSM is also superior to RWRMDA, MIDP, and MIDPE, and the average AUC are 6.5%, 3.3% and 2.4%, respectively, higher than other methods. The comparison results imply that KRLSM is also appropriate for prediction with sparse miRNA-disease associations.
Moreover, the top-ranked prediction results are shown in Table 3 and Supplementary Figure S1 , and KRLSM outperforms RWRMDA, MIDP, and MIDPE under different ranking thresholds. For instance, among the 5424 known miRNA-disease associations, KRLSM correctly predicted 36.28% (or 1968) and 74.54% (or 4043) known associations at the top 10 and top 50, respectively. The result indicates that our proposed method is more effective in identifying confirmed miRNA-disease associations and has a lower false positive rate than the compared methods.
In summary, all the above experimental results demonstrate that KRLSM exhibits the optimal performance using Kronecker regularized least squares by integrating heterogeneous omics data in terms of cross validation and top-ranked prediction, which further confirms that fully utilizing some prior information in similarity evaluations could enhance the prediction performance.
2) DE NOVO miRNA-DISEASE PREDICTION
To further verify the ability of KRLSM to discover potential miRNAs for new diseases, the de novo miRNA-disease prediction experiments are performed here. For a queried disease d, we remove all the known miRNA-disease associations related to disease d, and these associations are used as positive samples of the testing dataset when evaluating the performance of KRLSM and other methods. Because MIDP and RWRMDA could not identify potential associations for diseases with no known miRNAs, we only compared our method with MIDPE. Here, three common diseases were used as instances in the experiments, we removed 202, 132, and 118 known diseaserelated associations for breast neoplasms, lung neoplasms and prostatic neoplasms, respectively. As shown in Figure 4 , the AUC values of KRLSM corresponding to the three diseases are 0.832, 0.847, and 0.815. For MIDPE, the AUC values are 0.791, 0.828, and 0.804. KRLSM achieves slightly better performance than MIDPE. In addition, we also evaluated the performance by the recall, which means how many percentage of the experimentally confirmed associations between miRNAs and diseases are correctly identified under different ranking thresholds. The results of the selected diseases are given in Table 4 . It is observed that our method outperforms MIDPE in most of the situations, which demonstrates the power of our proposed method to recognize the true miRNAdisease associations. This may be due to the fact that the other correlation information, including the experimentally verified miRNA-gene interactions, the weighted gene-gene network, and the information of other diseases with known associated miRNAs, are fully exploited in our method. Overall, all these results confirm that KRLSM is able to predict potential associations for new diseases with no known associated miRNAs effectively.
D. EFFECTIVENESS OF THE COMPREHENSIVE SIMILARITY MEASURES
We also investigate the effectiveness of the improved similarity measures for KRLSM. The performances of two methods (KRLSM-GS, KRLSM) are evaluated by five-fold cross validation for the above mentioned 22 diseases. For KRLSM-GS, we apply the Gaussian kernel to calculate similarity for diseases and miRNAs, which means that only the known association information is involved in similarity measures. For KRLSM, the comprehensive similarity measures are used to estimate similarity, which develops the use of multiple heterogeneous biological information for prediction. The performance comparisons are shown in Figure 5 , and we can see that the performance of KRLSM is superior to KRLSM-GS for these diseases. For instance, the AUC values obtained by KRLSM for breast neoplasms, lung neoplasms, and prostatic neoplasms are 0.876, 0.911, and 0.845, whereas the AUC values achieved by KRLSM-GS are 0.794, 0.886, and 0.833, respectively. According to the results, we can conclude that the comprehensive similarity measures can enhance the prediction performance.
E. CASE STUDIES
To further demonstrate the capability of KRLSM for prioritizing disease-related miRNAs, case studies are conducted. Here, all the known associations between miRNAs and diseases are used as training set. The reminding associations constitute the set of candidate associations. The prediction candidate miRNAs of each selected disease are confirmed by literature and three public databases: miRCancer [36] , dbDEMC [37] and PhenomiR2.0 [38] .
In this section, several common diseases are chosen as examples. Breast cancer is one of the most common cancer and lead to a large number of deaths every year. The top 30 predicted miRNA candidates for breast neoplasms are shown VOLUME 5, 2017 in Table 5 . From the table, 83.3% of these miRNAs have been directly validated to be related to breast cancer by the three aforementioned databases, and only 5 miRNAs were not confirmed. Moreover, some candidate miRNAs predicted by KRLSM also have high rankings in some other methods, such as HDMP [18] and MIDP [20] . The top 10 predicted miRNAs of our method and MIDP for the selected diseases are listed in Table 6 . Meanwhile, the number of overlap miRNAs for the three methods within top 50 are displayed in Figure 6 .
For lung neoplasm, 27 out of the top 30 miRNA candidates are directly correlated the neoplasm by the three databases. Some candidates are supported to be associated with lung cancer by the literature, such as hsa-mir-378a [39] and hsa-mir-708 [40] . Detailed information is presented in Supplementary Table S2 . Moreover, 26 miRNA candidates have been identified by MIDP and HDMP within top 50 (Supplementary Figure S2) , which indirectly confirmed these candidates are expected to be related to lung neoplasms. In the similarity way, the case study of prostatic neoplasms is conducted and detailed information is given in Supplementary Table S3 and Figure S3 . In addition, the network of the top 30 predicted associations for breast neoplasms, lung neoplasms and prostatic neoplasms by our method is shown in Figure 7 . It is observed that some top-ranked miRNAs are associated with one or more diseases. In summary, the prediction instances further indicate the KRLSM is effective for identifying the disease-related miRNAs. The predictions for all diseases are listed in Supplementary Table S4 .
Except for validating the prediction candidate miRNAs with literature and public databases, we also performed functional enrichment analysis based on TAM (http://cmbi.bjmu. edu.cn/tam) [41] , which is a free online tool for annotations of human miRNAs. The purpose of the functional analysis is to investigate whether the functions of miRNAs (including the known miRNAs and the top 30 potential miRNAs) are involved in cancer development. As shown in Figure 8 , among the 232 miRNAs that are related to breast cancer, 63 miRNAs are concerned with human embryonic stem cell regulation, and 55 miRNAs are associated with cell cycle related functions. In addition, 48, 38 and 44 miRNAs are involved in hormones regulation, apoptosis and cell death, respectively. Accumulating evidence has demonstrated that all the above functions play critical roles in cancer development. For instance, several studies indicated that the abnormal stem cells may cause tumors and result in many types of cancer [42] , [43] . Clearly, cell death and apoptosis are also related to breast cancer. More detailed information is presented in Supplementary Table S5 . Overall, these cancerrelated miRNAs are involved in some crucial biological processes and many of them may cause cancers.
IV. CONCLUSIONS
The prioritization of potential disease-related miRNAs is a very challenging and meaningful work for polygenic disease research. In this study, we developed a novel method, called KRLSM, for discovering potential associations between miRNAs and diseases. First, the similarity measurements are presented to estimate the similarity between miRNAs or diseases by integrating some useful heterogeneous information. This step is influential in discovering the miRNA candidates for these diseases without known associated miRNAs. Subsequently, the Kronecker regularized least squares-based semi-supervised framework is used to identify the disease miRNAs. The superior performance of KRLSM is confirmed by cross validation experiment, top-ranked prediction, and de novo experiment compared with other popular methods. The impact of our comprehensive similarity measures is also investigated by cross validation, which confirms the effectiveness by using multiple data sources for prediction. Furthermore, case studies about several common diseases further verify the predictive ability of KRLSM for discovering miRNA-disease associations.
Despite the practicability and efficiency of KRLSM, some limitations also exist and need to be improved in the future. First, multiple parameters are involved in our method and establishing the optimal parameter values remain a challenging problem. Second, the similarity metrics for KRLSM could not be optimal, and a more rational integration of different omics data to improve prediction performance should be developed. Finally, although KRLSM obtains significant performance, current prediction performance remains unsatisfactory and needs further improvement. 
